Inflammation-Related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy

X. Pu, M. A T Hildebrandt, C. Lu, J. A. Roth, D. J. Stewart, Y. Zhao, R. S. Heist, Y. Ye, D. W. Chang, L. Su, J. D. Minna, S. M. Lippman, M. R. Spitz, D. C. Christiani, X. Wu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Accurate prognostic prediction is challenging for patients with advanced-stage non-small cell lung cancer (NSCLC). We systematically investigated genetic variants within inflammation pathways as potential prognostic markers for advanced-stage NSCLC patients treated with first-line chemotherapy. A discovery phase in 502 patients and an internal validation phase in 335 patients were completed at the MD Anderson Cancer Center. External validation was performed in 371 patients at Harvard University. A missense single-nucleotide polymorphism (SNP) in the gene encoding the major histocompatibility complex class II, DO-β chain (HLA-DOB:rs2071554), predicted to influence protein function, was significantly associated with poor survival in the discovery (hazard ratio (HR): 1.46; 95% confidence interval (CI): 1.02-2.09), internal validation (HR: 1.51; 95% CI: 1.02-2.25), and external validation (HR: 1.52; 95% CI: 1.01-2.29) populations. KLRK1:rs2900420 was associated with reduced risk in the discovery (HR: 0.76; 95% CI: 0.60-0.96), internal validation (HR: 0.77; 95% CI: 0.61-0.99), and external validation (HR: 0.80; 95% CI: 0.63-1.02) populations. A strong cumulative effect on overall survival was observed for these SNPs. Genetic variations in inflammation-related genes could have potential to complement prediction of prognosis.

Original languageEnglish (US)
Pages (from-to)360-369
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume96
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Confidence Intervals
Inflammation
Drug Therapy
Survival
Single Nucleotide Polymorphism
Major Histocompatibility Complex
Population
Genes
Neoplasms
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Inflammation-Related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. / Pu, X.; Hildebrandt, M. A T; Lu, C.; Roth, J. A.; Stewart, D. J.; Zhao, Y.; Heist, R. S.; Ye, Y.; Chang, D. W.; Su, L.; Minna, J. D.; Lippman, S. M.; Spitz, M. R.; Christiani, D. C.; Wu, X.

In: Clinical Pharmacology and Therapeutics, Vol. 96, No. 3, 2014, p. 360-369.

Research output: Contribution to journalArticle

Pu, X, Hildebrandt, MAT, Lu, C, Roth, JA, Stewart, DJ, Zhao, Y, Heist, RS, Ye, Y, Chang, DW, Su, L, Minna, JD, Lippman, SM, Spitz, MR, Christiani, DC & Wu, X 2014, 'Inflammation-Related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy', Clinical Pharmacology and Therapeutics, vol. 96, no. 3, pp. 360-369. https://doi.org/10.1038/clpt.2014.89
Pu, X. ; Hildebrandt, M. A T ; Lu, C. ; Roth, J. A. ; Stewart, D. J. ; Zhao, Y. ; Heist, R. S. ; Ye, Y. ; Chang, D. W. ; Su, L. ; Minna, J. D. ; Lippman, S. M. ; Spitz, M. R. ; Christiani, D. C. ; Wu, X. / Inflammation-Related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. In: Clinical Pharmacology and Therapeutics. 2014 ; Vol. 96, No. 3. pp. 360-369.
@article{549d09aa335d4f0ba3e6dcaad76af65e,
title = "Inflammation-Related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy",
abstract = "Accurate prognostic prediction is challenging for patients with advanced-stage non-small cell lung cancer (NSCLC). We systematically investigated genetic variants within inflammation pathways as potential prognostic markers for advanced-stage NSCLC patients treated with first-line chemotherapy. A discovery phase in 502 patients and an internal validation phase in 335 patients were completed at the MD Anderson Cancer Center. External validation was performed in 371 patients at Harvard University. A missense single-nucleotide polymorphism (SNP) in the gene encoding the major histocompatibility complex class II, DO-β chain (HLA-DOB:rs2071554), predicted to influence protein function, was significantly associated with poor survival in the discovery (hazard ratio (HR): 1.46; 95{\%} confidence interval (CI): 1.02-2.09), internal validation (HR: 1.51; 95{\%} CI: 1.02-2.25), and external validation (HR: 1.52; 95{\%} CI: 1.01-2.29) populations. KLRK1:rs2900420 was associated with reduced risk in the discovery (HR: 0.76; 95{\%} CI: 0.60-0.96), internal validation (HR: 0.77; 95{\%} CI: 0.61-0.99), and external validation (HR: 0.80; 95{\%} CI: 0.63-1.02) populations. A strong cumulative effect on overall survival was observed for these SNPs. Genetic variations in inflammation-related genes could have potential to complement prediction of prognosis.",
author = "X. Pu and Hildebrandt, {M. A T} and C. Lu and Roth, {J. A.} and Stewart, {D. J.} and Y. Zhao and Heist, {R. S.} and Y. Ye and Chang, {D. W.} and L. Su and Minna, {J. D.} and Lippman, {S. M.} and Spitz, {M. R.} and Christiani, {D. C.} and X. Wu",
year = "2014",
doi = "10.1038/clpt.2014.89",
language = "English (US)",
volume = "96",
pages = "360--369",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Inflammation-Related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy

AU - Pu, X.

AU - Hildebrandt, M. A T

AU - Lu, C.

AU - Roth, J. A.

AU - Stewart, D. J.

AU - Zhao, Y.

AU - Heist, R. S.

AU - Ye, Y.

AU - Chang, D. W.

AU - Su, L.

AU - Minna, J. D.

AU - Lippman, S. M.

AU - Spitz, M. R.

AU - Christiani, D. C.

AU - Wu, X.

PY - 2014

Y1 - 2014

N2 - Accurate prognostic prediction is challenging for patients with advanced-stage non-small cell lung cancer (NSCLC). We systematically investigated genetic variants within inflammation pathways as potential prognostic markers for advanced-stage NSCLC patients treated with first-line chemotherapy. A discovery phase in 502 patients and an internal validation phase in 335 patients were completed at the MD Anderson Cancer Center. External validation was performed in 371 patients at Harvard University. A missense single-nucleotide polymorphism (SNP) in the gene encoding the major histocompatibility complex class II, DO-β chain (HLA-DOB:rs2071554), predicted to influence protein function, was significantly associated with poor survival in the discovery (hazard ratio (HR): 1.46; 95% confidence interval (CI): 1.02-2.09), internal validation (HR: 1.51; 95% CI: 1.02-2.25), and external validation (HR: 1.52; 95% CI: 1.01-2.29) populations. KLRK1:rs2900420 was associated with reduced risk in the discovery (HR: 0.76; 95% CI: 0.60-0.96), internal validation (HR: 0.77; 95% CI: 0.61-0.99), and external validation (HR: 0.80; 95% CI: 0.63-1.02) populations. A strong cumulative effect on overall survival was observed for these SNPs. Genetic variations in inflammation-related genes could have potential to complement prediction of prognosis.

AB - Accurate prognostic prediction is challenging for patients with advanced-stage non-small cell lung cancer (NSCLC). We systematically investigated genetic variants within inflammation pathways as potential prognostic markers for advanced-stage NSCLC patients treated with first-line chemotherapy. A discovery phase in 502 patients and an internal validation phase in 335 patients were completed at the MD Anderson Cancer Center. External validation was performed in 371 patients at Harvard University. A missense single-nucleotide polymorphism (SNP) in the gene encoding the major histocompatibility complex class II, DO-β chain (HLA-DOB:rs2071554), predicted to influence protein function, was significantly associated with poor survival in the discovery (hazard ratio (HR): 1.46; 95% confidence interval (CI): 1.02-2.09), internal validation (HR: 1.51; 95% CI: 1.02-2.25), and external validation (HR: 1.52; 95% CI: 1.01-2.29) populations. KLRK1:rs2900420 was associated with reduced risk in the discovery (HR: 0.76; 95% CI: 0.60-0.96), internal validation (HR: 0.77; 95% CI: 0.61-0.99), and external validation (HR: 0.80; 95% CI: 0.63-1.02) populations. A strong cumulative effect on overall survival was observed for these SNPs. Genetic variations in inflammation-related genes could have potential to complement prediction of prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84907873759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907873759&partnerID=8YFLogxK

U2 - 10.1038/clpt.2014.89

DO - 10.1038/clpt.2014.89

M3 - Article

VL - 96

SP - 360

EP - 369

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -